Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of Tandem Diabetes Care, Inc. (NASDAQ:TNDM), that sends out a positive message to the company's shareholders.
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.
View our latest analysis for Tandem Diabetes Care
Tandem Diabetes Care Insider Transactions Over The Last Year
The Executive VP & COO, David Berger, made the biggest insider sale in the last 12 months. That single transaction was for US$201k worth of shares at a price of US$65.00 each. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. The silver lining is that this sell-down took place above the latest price (US$57.26). So it may not tell us anything about how insiders feel about the current share price.
Happily, we note that in the last year insiders paid US$511k for 7.00k shares. On the other hand they divested 3.50k shares, for US$244k. In total, Tandem Diabetes Care insiders bought more than they sold over the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
NasdaqGM:TNDM Insider Trading Volume September 18th 2022
There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).
Insider Ownership Of Tandem Diabetes Care
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. It appears that Tandem Diabetes Care insiders own 0.5% of the company, worth about US$20m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
What Might The Insider Transactions At Tandem Diabetes Care Tell Us?
There haven't been any insider transactions in the last three months -- that doesn't mean much. But insiders have shown more of an appetite for the stock, over the last year. Insiders do have a stake in Tandem Diabetes Care and their transactions don't cause us concern. Of course, the future is what matters most. So if you are interested in Tandem Diabetes Care, you should check out this free report on analyst forecasts for the company.
Of course Tandem Diabetes Care may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
通常情况下,当一个内部人士购买股票时,可能不会是一个重大事件。但当多个内部人士都在买入,就像他们在Tandem糖尿病护理公司(纳斯达克:TNDM),这向公司股东发出了一个积极的信息。
虽然我们永远不会建议投资者应该完全根据公司董事的所作所为做出决定,但我们确实认为,密切关注内部人士的所作所为是完全合乎逻辑的。
查看我们对串联糖尿病护理的最新分析
去年Tandem糖尿病护理内幕交易
执行副总裁兼首席运营官大卫·伯杰在过去12个月中进行了最大规模的内幕交易。这一笔交易是以每股65.00美元的价格收购了价值20.1万美元的股票。我们通常不喜欢看到内幕销售,但售价越低,我们就越担心。一线希望是,这次抛售发生在最新价格(57.26美元)之上。因此,它可能不会告诉我们任何关于内部人士对当前股价的感受。
令人高兴的是,我们注意到,在去年,内部人士支付了51.1万美元购买了7.00万股。另一方面,他们以24.4万美元的价格剥离了3.5万股。总体而言,Tandem糖尿病护理内部人士在过去一年里买的比卖的多。你可以在下面看到过去12个月(由公司和个人)进行的内幕交易的直观描述。通过点击下面的图表,你可以看到每一笔内幕交易的准确细节!
NasdaqGM:TNDM内幕交易量2022年9月18日
内部人士总是在买入大量股票。因此,如果这适合你的风格,你可以逐一检查每一种库存,或者你可以看看这个免费公司名单。(提示:内部人士一直在买入这些股票)。
串联糖尿病护理的内部人所有权
另一种测试公司领导人与其他股东之间一致性的方法是看他们拥有多少股份。我们通常希望看到相当高水平的内部人士持股。似乎Tandem糖尿病护理内部人士拥有该公司0.5%的股份,价值约2000万美元。我们当然在其他地方看到了更高水平的内部人持股,但这些持股足以表明内部人和其他股东之间的关系。
Tandem糖尿病护理公司的内幕交易可能告诉我们什么?
过去三个月没有发生任何内幕交易--这并不意味着什么。但在过去一年里,内部人士对该股表现出了更大的兴趣。内部人士确实拥有Tandem糖尿病护理公司的股份,他们的交易不会引起我们的担忧。当然了,未来才是最重要的。因此,如果你对串联糖尿病护理感兴趣,你应该看看这个免费分析师对该公司的预测报告。
当然了Tandem糖尿病护理可能不是购买的最佳股票。所以你可能想看看这个免费汇集了高质量的公司。
就本文而言,内部人是指向相关监管机构报告其交易的个人。我们目前负责公开市场交易和私人处置,但不包括衍生品交易。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。